<(p-Nitrophenyl)ethyl>-β-sulfonic ester | 20020-28-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: <(p-Nitrophenyl)ethyl>-β-sulfonic ester
• 英文别名: methanesulfonic acid 2-(4-nitrophenyl)ethyl ester；2-(4'-nitrophenyl)ethyl methanesulfonate；2-(4-nitrophenyl)ethyl methanesulfonate；4-nitrophenethyl alcohol methanesulfonate；2-(4-Nitrophenyl)-aethanol-mesylat
• CAS: 20020-28-4
• 化学式: C₉H₁₁NO₅S
• 分子量: 245.256
• InChiKey: ACIXWGULTDZTFA-UHFFFAOYSA-N

物化性质

• 沸点：
  459.5±28.0 °C(Predicted)
• 密度：
  1.377±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  97.6
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  <(p-Nitrophenyl)ethyl>-β-sulfonic ester 在 positively charged azoniacyclophane CP₆₆ 作用下， 生成 4-硝基苯乙烯
  参考文献：
  名称：

  Host-guest chemistry. Part 30. Salt effects on supramolecular complexation and catalysis

  摘要：

  Complexation equilibria between a positively charged azoniacyclophane (CP66) and naphthalene-2-carboxylate in water show a linear Debye-Huckel correlation with a sensitivity of m = -1.5 compared to the m = -4.1 for pure ionic complexes observed experimentally and predicted theoretically. The m values can be used as a scale for ionic vs lipophilic van der Waals binding contributions; the latter dominate in the present azoniacyclophane complexes. Complexation-induced NMR shifts (CIS) vary from -0.3 ppm to -1.6 ppm shielding and demonstrate in all cases intracavity inclusion with different geometries. The cyclophane CP66 enhances rates of nucleophilic substitution of 1-chloro-2,6-dinitrobenzoic acid (2) with OH- by a factor of up to approximately 2, with NO2- by up to approximately 8. The elimination from 2-(p-nitrophenyl)ethyl mesylate to p-nitrostyrene under basic conditions is enhanced by up to approximately 5; the saturation curve obtained in this case indicates a limiting k(cat)/k(un) is-approximately-equal-to 10 and a binary complex constant of K almost-equal-to 15 M-1. Salt effect studies show that a considerable part of the rate enhancements by macrocyclic polyammonium ions can be due to the increase of ionic strength as a consequence of the multiple charges in the catalyst. The ionic strength/salt effect contribution is large in the reaction of 2 with OH-, but smaller for the other two reactions.

  DOI：

  10.1021/jo00037a022
• 作为产物：
  描述：

  对硝基苯乙酸 在 吡啶 、 dimethyl sulfide borane 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 生成 <(p-Nitrophenyl)ethyl>-β-sulfonic ester
  参考文献：
  名称：

  DNA-directed alkylating agents. 2. Synthesis and biological activity of platinum complexes linked to 9-anilinoacridine

  摘要：

  Two different classes of cis-diaminedichloroplatinum(II) complexes linked to the DNA-intercalating chromophore 9-anilinoacridine have been synthesized and evaluated as DNA-targeted antitumor agents. Two different Pt chelating ligands were investigated (based on 1,2-ethanediamine and 1,3-propanediamine), designed to deliver the Pt in an orientation likely to respectively enhance either intrastrand or interstrand cross-linking. Although both sets of ligands were somewhat unstable under neutral or basic conditions with respect to disproportionation, the corresponding Pt complexes, once prepared, appeared to be quite stable. All the Pt complexes were monitored for purity by TLC, HPLC, and FAB mass spectra, and the mode of Pt coordination was established by 195Pt NMR spectroscopy. The complexes appeared to cause simultaneous platination and intercalative unwinding of plasmid DNA. In vitro studies were carried out with both wild-type and cisplatin-resistant P388 cell lines. Whereas cisplatin itself and the ethylenediamine and 1,3-propanediamine complexes used as standards were about 10-fold less active against the resistant line, the ethylenediamine-linked Pt complexes showed no differential toxicity between the two lines and the propanediamine-linked complexes showed significant differentials (up to 8-fold) in favor of the cisplatin-resistant line. However, these were no greater than those shown by the unplatinated ligands themselves. The majority of the acridine complexes were inactive in vivo against the wild-type P388 leukemia. They were very insoluble, and although a suitable formulation was found, this may have been a factor. It is also possible that these compounds bind in such a way as to direct the Pt away from the major groove.

  DOI：

  10.1021/jm00173a015

文献信息

• Sustainable organophosphorus-catalysed Staudinger reduction
  作者：Danny C. Lenstra、Peter E. Lenting、Jasmin Mecinović

  DOI：10.1039/c8gc02136h

  日期：——

  A highly efficient and sustainable catalytic Staudinger reduction for the conversion of organic azides to amines in excellent yields has been developed. The reaction displays excellent functional group tolerance to functionalities that are otherwise prone to reduction, such as sulfones, esters, amides, ketones, nitriles, alkenes, and benzyl ethers. The green nature of the reaction is exemplified by

  已经开发出一种高效且可持续的Staudinger催化还原方法，用于以优异的产率将有机叠氮化物转化为胺。该反应对优异的官能团具有极好的官能团耐受性，这些官能团否则容易还原，例如砜，酯，酰胺，酮，腈，烯烃和苄基醚。通过使用PMHS，CPME和缺少柱色谱法可以举例说明反应的绿色性质。
• Para-phenylalkoxy phenylurea and thiourea compounds and herbicidal use
  申请人：American Cyanamid Company

  公开号：US04289903A1

  公开（公告）日：1981-09-15

  There are provided certain p-phenylalkoxy phenylurea and thiourea compounds useful for the control of undesirable plants in the presence of agronomic crops and to methods for the preparation of said phenylalkoxy phenylurea and thiourea compounds.

  提供了一些对农业作物中不需要的植物控制有用的对苯基烷氧基苯基脲和硫脲化合物，以及用于制备所述对苯基烷氧基苯基脲和硫脲化合物的方法。
• [EN] MATRIX METALLOPROTEINASE INHIBITORS<br/>[FR] INHIBITEURS DE MÉTALLOPROTÉINASE MATRICIELLE
  申请人：RANBAXY LAB LTD

  公开号：WO2012038942A1

  公开（公告）日：2012-03-29

  This invention also relates to pharmacological compositions containing the compounds of the present invention, and methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, dry eye, neointimal proliferation, which leads to restenosis and ischemic heart faliure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by over-expression and over-activation of matrix metalloproteinase using the compounds.

  这项发明还涉及含有本发明化合物的药物组合物，以及治疗哮喘、类风湿关节炎、慢性阻塞性肺病、鼻炎、骨关节炎、银屑病性关节炎、银屑病、肺纤维化、肺部炎症、急性呼吸窘迫综合征、牙周炎、多发性硬化症、牙龈炎、动脉粥样硬化、干眼症、新生内膜增生，导致再狭窄和缺血性心力衰竭、中风、肾脏疾病、肿瘤转移，以及使用这些化合物治疗过度表达和过度活化基质金属蛋白酶的其他炎症性疾病的方法。
• MATRIX METALLOPROTEINASE INHIBITORS
  申请人：RANBAXY LABORATORIES LIMITED

  公开号：US20140148459A1

  公开（公告）日：2014-05-29

  This invention also relates to pharmacological compositions containing the compounds of the present invention, and methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, pulmonary inflammation, acute respiratory distress syndrome, periodontitis, multiple sclerosis, gingivitis, gingivitis, atherosclerosis, dry eye, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and pounds.

  这项发明还涉及含有本发明化合物的药物组合物，以及治疗哮喘、类风湿关节炎、慢性阻塞性肺病、鼻炎、骨关节炎、银屑病性关节炎、牛皮癣、肺纤维化、肺部炎症、急性呼吸窘迫综合征、牙周炎、多发性硬化症、牙龈炎、牙龈炎、动脉粥样硬化、干眼症、新生内膜增生导致再狭窄和缺血性心力衰竭、中风、肾脏疾病、肿瘤转移和磅的方法。
• 1, 2, 4-TRIAZOLONE DERIVATIVE
  申请人：Kuwada Takeshi

  公开号：US20130197217A1

  公开（公告）日：2013-08-01

  The present invention provides a 1,2,4-triazolone derivative represented by Formula (1A) having an antagonistic activity on the arginine-vasopressin 1b receptor or a pharmaceutically acceptable salt thereof and provides a pharmaceutical composition comprising the compound or the salt as an active ingredient, in particular, a therapeutic or preventive agent exhibiting favorable pharmacokinetics in a disease such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, or alopecia.

  本发明提供了一种1,2,4-三唑酮衍生物，其表示为式（1A），具有对精氨酸加压素1b受体的拮抗活性或其药用盐，并提供了包含该化合物或盐作为活性成分的药物组合物，特别是在诸如情绪障碍、焦虑障碍、精神分裂症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、进食障碍、高血压、胃肠疾病、药物成瘾、癫痫、脑梗死、脑缺血、脑水肿、头部损伤、炎症、免疫相关疾病或脱发等疾病中展现良好药代动力学的治疗或预防剂。